

Gestational Age:	
≤ 28 weeks and 6 days	<ul style="list-style-type: none"> • ≤ 12 months of age at the start of RSV season
CLD/CHD/Other:	
Chronic lung disease of prematurity (CLDP) defined as gestational age ≤ 31 weeks and 6 days and a requirement for > 21% oxygen for at least 28 days after birth	<ul style="list-style-type: none"> • ≤ 12 months of age at the start of RSV season • ≤ 24 months of age at the start of RSV season • Continue to require medical support (supplemental oxygen, chronic corticosteroid or diuretic therapy) during 6 month period before the start of RSV season. <p style="text-align: center;"><u>OR</u></p>
Hemodynamically significant congenital heart disease (CHD)	<ul style="list-style-type: none"> • ≤ 12 months of age at start of RSV season • Diagnosis of at least one of the following: <ul style="list-style-type: none"> ○ Ayanotic heart disease with medication to control congestive heart failure and will require cardiac surgical procedures ○ Infants with moderate to severe pulmonary hypertension ○ Cyanotic heart defects and referred by pediatric cardiologist <p style="text-align: center;"><u>OR</u></p> <ul style="list-style-type: none"> • ≤ 24 months of age at the start of RSV season • Cardiac transplantation during RSV season
Neuromuscular disorder or congenital anomaly that impairs the ability to clear secretions from the upper airway because of ineffective cough	<ul style="list-style-type: none"> • ≤ 12 months of age at start of RSV season
immunocompromised due to chemotherapy or other conditions	<ul style="list-style-type: none"> • ≤ 24 months of age at the start of RSV season • Profoundly immunocompromised during RSV season
Cystic Fibrosis (CF)	<ul style="list-style-type: none"> • Recommended if ≤ 12 months of age at start of RSV season and at least one of the following indications are present: <ul style="list-style-type: none"> ○ Evidence of CLD ○ Nutritional compromise <p style="text-align: center;"><u>OR</u></p> <ul style="list-style-type: none"> • If ≤ 24 months of age at the start of RSV season with at least one of the following manifestations of severe lung disease: <ul style="list-style-type: none"> ○ Previous hospitalization for pulmonary exacerbation in first year of life ○ Abnormalities on chest radiography or chest computed tomography that persist when stable • Weight for length less than the 10th percentile
<p>**Clinicians may administer up to a maximum of five monthly doses of Synagis (Palivizumab) during the RSV season to infants who qualify for prophylaxis in the first year of life. Qualifying infants born during the RSV season will require fewer doses**</p>	